Opin vísindi

Fletta eftir efnisorði "Lyf"

Fletta eftir efnisorði "Lyf"

Röðun: Raða: Niðurstöður:

  • Icon
    Áhrif lyfsins fampridíns á skerta göngugetu sjúklinga með MS (Multiple Sclerosis) 
    Guðjónsdóttir, Björg; Hjaltason, Haukur; Andrésdóttir, Guðbjörg Þóra (2021-04)
    INTRODUCTION: Fampridine is a drug for people with Multiple Sclerosis (MS). It is a broad-spectrum voltage-dependent potassium channel blocker that enhances synaptic transmission. The drug has been shown to be able to enhance conduction in demyelinated ...
  • Icon
    Cognitive effects of montelukast : A pharmaco-eeg study 
    Schwimmbeck, Fabian; Staffen, Wolfgang; Höhn, Christopher; Rossini, Fabio; Renz, Nora; Lobendanz, Markus; Reichenpfader, Peter; Iglseder, Bernhard; Aigner, Ludwig; Trinka, Eugen; Höller, Yvonne (2021-05)
    Montelukast is a well-established antiasthmatic drug with little side effects. It is a leukotriene receptor antagonist and recent research suggests cognitive benefits from its anti-inflammatory actions on the central nervous system. However, changes ...
  • Icon
    Generating real-world evidence on the quality use, benefits and safety of medicines in australia : History, challenges and a roadmap for the future 
    Pearson, Sallie Anne; Pratt, Nicole; Costa, Juliana de Oliveira; Zoéga, Helga; Laba, Tracey Lea; Etherton-Beer, Christopher; Sanfilippo, Frank M.; Morgan, Alice; Ellett, Lisa Kalisch; Bruno, Claudia; Kelty, Erin; Ijzerman, Maarten; Preen, David B.; Vajdic, Claire M.; Henry, David (2021-12-18)
    Australia spends more than $20 billion annually on medicines, delivering significant health benefits for the population. However, inappropriate prescribing and medicine use also result in harm to individuals and populations, and waste of precious health ...
  • Icon
    The glaucoma intensive treatment study : interim results from an ongoing longitudinal randomized clinical trial 
    Bengtsson, Boel; Lindén, Christina; Heijl, Anders; Andersson-Geimer, Sabina; Aspberg, Johan; Jóhannesson, Gauti (2021-07-29)
    Purpose: The aim of the study was to determine the perimetric rate of glaucoma progression in the ongoing Glaucoma Intensive Treatment Study (GITS) after 3 years of follow-up. Design: This is a randomized, two-centre, prospective open-labelled treatment ...
  • Icon
    Medicine treatment of glaucoma in Australia 2012-2019 : Prevalence, incidence and persistence 
    Daniels, Benjamin; Healey, Paul; Bruno, Claudia; Kaan, Iain; Zoéga, Helga (2021-12-30)
    Objective Medical therapy can halt or significantly slow the progression of glaucoma if medicines are used in accordance with the guidelines. We used dispensing claims for a 10% sample of all Australians dispensed publicly subsidised glaucoma medicines ...
  • Icon
    New prodrugs and analogs of the phenazine 5,10-dioxide natural products iodinin and myxin promote selective cytotoxicity towards human acute myeloid leukemia cells 
    Viktorsson, Elvar Örn; Aesoy, Reidun; Støa, Sindre; Lekve, Viola; Døskeland, Stein Ove; Herfindal, Lars; Rongved, Pål (2021-05)
    Novel chemotherapeutic strategies for acute myeloid leukemia (AML) treatment are called for. We have recently demonstrated that the phenazine 5,10-dioxide natural products iodinin ( 3) and myxin ( 4) exhibit potent and hypoxia-selective cell death on ...
  • Icon
    NSAID use and unnatural deaths after cancer diagnosis : a nationwide cohort study in Sweden 
    Shen, Qing; Sjölander, Arvid; Sloan, Erica K.; Walker, Adam K.; Fall, Katja; Valdimarsdóttir, Unnur Anna; Sparén, Pär; Smedby, Karin E.; Fang, Fang (2022-01-17)
    Background: Cancer patients experience increased risk of death from accident and suicide. Cognitive impairment induced by cancer-related inflammation and stress-related psychiatric symptoms may be underlying mechanisms. We therefore studied the association ...
  • Icon
    Töflur og töflugerð. Með sérstöku tilliti til íslenskra aðstæðna. 
    Skaftason, Jóhannes F; Jóhannesson, Þorkell (2013-04)
    Töfluslátta hófst í Englandi 1844. Fyrstu töflur innihéldu vatnsleysin sölt samkvæmt forskrift Brockedons og voru sennilega slegnar án hjálparefna. Tímamót urðu um 1887 þegar tekið var að nota mjölva (amylum maydis) í Bandaríkjunum til þess að sundra ...
  • Icon
    Vioxx - víti til varnaðar? 
    Guðmundsson, Sigurður (2004-11-01)
    Þann 30. september síðastliðinn bárust þau óvenjulegu tíðindi að framleiðandi rófecoxíbs (Vioxx®), lyfja­fyrirtækið Merck, Sharp & Dohme hafi tekið lyfið af markaði vegna nýrra upplýsinga um aukna áhættu af völdum blóðsegamyndunar, kransæða­stíflu og ...